表纸
市场调查报告书
商品编码
346223

印度的医药品市场未来预测 (2019~2019年)

Indian Pharmaceutical Market Forecast 2019-2029

出版日期: | 出版商: Visiongain Ltd | 英文 212 Pages | 商品交期: 最快1-2个工作天内

价格
  • 全貌
  • 简介
  • 目录
简介

印度的医药品市场将在2018年达到288亿美元的规模,在2019年~2024年间预测将以16.6%的年复合成长率 (CAGR) 持续成长。尤其是,心血管疾病和感染疾病的治疗药需求今后预计将大幅增加。

本报告提供印度的医药品市场相关调查分析,市场基本结构和背景情况,收益趋势的预测,主要企业的评估,促进因素、阻碍因素,预测等系统性资讯。

第1章 报告概要

第2章 印度的医疗:概要

  • 印度:人口统计指标概要
  • 印度的医疗制度:概要
    • Rashtriya Swasthya Bima Yojana:最底层劳工用医疗保险的提供
  • 印度的医疗费分析

第3章 印度的医药品的管理体制

  • 监督机构
    • 医疗、家庭福利省 (MoHFW)
    • 化学产品、肥料省 (MoC&F)
  • 政府的相关机关
  • 印度的医药品市场的法规、规定:一览
  • 市场进入
    • 医疗制度
    • HTA (Health Technology Assessment)的现状
    • 药价趋势
    • 医药品的医疗费偿付

第4章 印度的医药品市场:讨论与预测

  • 在世界第3大大市场
  • 市场收益额的预测值 (总额,今后12年份)

第5章 印度国内的医疗需求

  • 各种疾病的患病人数 (今后11年份)
  • 各种疾病的发病数量 (今后11年份)
  • 各种疾病的死亡率 (今后11年份)
    • 印度国内的主要的死因
    • 主要的死因:死亡率的预测 (今后11年份)

第5章 印度的医药品市场:主要的治疗领域

  • 主要的治疗领域:概要
  • 市场预测:主要的各治疗领域 (今后11年份)
  • 感染疾病治疗药
    • 市场预测 (今后11年份)
      • 腹泻
      • 下呼吸道感染疾病
      • 结核
      • 疟疾
      • HIV
    • 推动及阻碍市场要素
  • 心血管疾病治疗药
  • 肠胃疾病治疗药
  • 呼吸疾病治疗药
  • 疼痛缓和药/止痛药
  • 糖尿病治疗药
  • 维他命/矿物质/营养剂
  • 皮肤病治疗药
  • 中枢神经系统 (CNS) 疾病治疗药
  • 妇产科疾病治疗药
  • 其他的疾病的治疗药

第7章 印度的医药品市场:主要药物的种类

  • 印度市场上医药品的种类:概要
  • 主要种类的医药品的成长率预测 (今后11年份)
  • 学名药 - 印度占市场大半部分存在
    • 市场预测 (今后11年份)
    • 推动及阻碍市场要素等
  • 成药
  • 专利医药品
  • 生物相似药医药品

第8章 印度的医药品市场代表性企业

  • 印度的医药品市场:概要
    • 对于印度的医药品相关的专利法,和大型制药企业的影响力
  • 印度国内的制药企业前50大企业
  • Sun Pharmaceuticals Industries Limited
    • 业绩趋势 (过去10年份)
    • 企业发展/资本交易趋势
  • Abbott Healthcare Private Limited (Abbott India)
  • Cipla Ltd.
  • Cadila Healthcare Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer Limited., India
  • Lupin
  • Sanofi India Limited
  • Intas Pharmaceuticals Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited

第9章 印度的医药品市场定性分析

  • 印度的医药品市场:促进、阻碍因素
  • 印度的医药品市场SWOT分析
  • 优势
    • 医疗制度的投资扩大
    • 疾病负担、GDP的增加
    • 印度的总人口:2030年成为世界最大
    • 作为制药产业的外包处有前途的印度
  • 弱点
    • 来自严格的价格法规对市场的不良影响
    • 由于贫乏的医疗基础设施,潜在的市场缩小
    • 竞争激烈伴随的药价降低
  • 机会
    • 世界规模的学名药需求增加
    • 国家农村健康任务 (NRHM):农村的医疗获取的改善
    • 由跨国公司 (MNC) 的巨额投资预测
    • 作为良机跃进创新的生物科技部门:专利到期
  • 威胁
    • 学名药:其他低成本出口国的崛起
    • 印度政府今后也将维持医疗费的增额趋势吗?
    • 来自当局近几年的警告和禁止出口令:制药企业的自信丧失
  • 波特的五力分析
    • 企业间竞争 (高)
    • 新加入企业的威胁 (低)
    • 供应商谈判力 (中)
    • 买主谈判力 (高)
    • 替代产品的威胁 (低)

第10章 结论

  • 印度的医药品市场:全球市场的占有率的扩大
  • 慢性疾病患者的剧增
  • 推动市场要素
  • 阻碍市场要素
  • 分析结果

第11章 用语一览

目录
Product Code: PHA0419

The Indian pharmaceuticals market is estimated to have reach $28.8bn in 2018 and is expected to grow at a CAGR of 16.6% in the first half of the forecast period. The market for cardiovascular medication is the fastest growing segment of the Indian pharmaceutical market, followed by the anti-infective segment.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 212-page report you will receive 121 charts - all unavailable elsewhere.

The 212-page report provides clear detailed insight into the Indian Pharmaceutical Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Indian Pharmaceuticals Market forecasts from 2019-2029

Revenue forecasts for the leading therapeutic areas in India from 2019-2029:

  • Anti-Infectives Therapeutics
  • Cardiovascular Therapeutics
  • Dermatological Therapeutics
  • Diabetes Therapeutics
  • Gastrointestinal Therapeutics
  • Gynaecology Therapeutics
  • CNS Therapeutics
  • Pain Relief/Analgesics Therapeutics
  • Respiratory Therapeutics
  • Vitamins/Minerals/Nutrients Therapeutics
  • Other Therapeutics

This report also discusses factors that drive and restrain these submarkets.

Revenue forecasts for the leading drug types in India from 2019-2029:

  • Generic Drugs
  • Over-the-Counter (OTC) Drugs
  • Patented Drugs
  • Biosimilar Drugs

This report also discusses factors that drive and restrain these submarkets.

Profiles and discusses the leading companies in the Indian pharmaceutical market:

  • Abbott Healthcare Private Limited (Abbott India)
  • Cadila Healthcare Limited
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Limited
  • Lupin
  • Pfizer Limited
  • Sanofi India Limited
  • Sun Pharmaceuticals Industries Limited

(Revenues are provided for those companies whose financial information is available on the public domain)

  • Analysis of the drivers and restraints of the Indian Pharmaceutical market
  • The report also discusses the Porter's Five Forces Analysis and SWOT Analysis of the Indian Pharmaceuticals Market

This report also discusses:

  • Indian healthcare system and Indian healthcare expenditure
  • Indian pharmaceutical regulatory framework, laws & regulations, market access, regulatory bodies
  • Disease prevalence and incidence in India, disease mortality rates in India, top causes of death in India, mortality projections from 2019-2029

What this report provides:

  • The Indian pharmaceutical market forecasts and analysis from 2019 to 2029
  • Analysis and forecasts for the Indian pharmaceutical submarkets from 2019 to 2029
  • Profiles of the leading companies operating within the Indian pharmaceutical industry
  • SWOT analysis and Porter's five forces analysis of the major strengths and weaknesses of the Indian pharmaceutical market together with the opportunities available and the key threats faced

Visiongain's study is intended for anyone requiring commercial analyses for the Indian Pharmaceuticals Market. You find data, trends and predictions.

Buy our report today Indian Pharmaceutical Market Forecast 2019-2029: Infectious Disease, Cardiovascular, Gastrointestinal, Respiratory, Pain Relief / Analgesics, Diabetes, Vitamins/ Minerals/ Nutrients, Dermatology, CNS, Gynaecology, Generic, OTC, Patented, Biosimilar, Leading Companies’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 The Indian Pharmaceutical Market Overview
  • 1.2 Indian Pharmaceutical Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Indian Healthcare: Overview

  • 2.1 India: Demographic Indicators Overview
  • 2.2 Indian Healthcare System: Overview
    • 2.2.1 Rashtriya Swasthya Bima Yojana - Bringing Healthcare Coverage to India's Poorest Workers
  • 2.3 Analysis of India's Healthcare Expenditure

3. Indian Pharmaceutical Regulatory Framework

  • 3.1 National Regulatory Bodies
    • 3.1.1 Ministry of Health & Family Welfare (MoHFW)
    • 3.1.2 Ministry of Chemicals and Fertilizers (MoC&F)
  • 3.2 State Regulatory Bodies (State Food and Drug Administrations (FDAs)
  • 3.3 Laws & Regulations for Indian Pharmaceutical Market
    • 3.3.1 The Drugs and Cosmetics Act, 1940
    • 3.3.2 The Pharmacy Act, 1948
    • 3.3.3 The Drugs & Magic Remedies Act, 1954
    • 3.3.4 The Narcotic Drugs and Psychotropic Substances Act, (NDPS)1985
    • 3.3.5 The Medicinal and Toilet Preparations Act, 1956
    • 3.3.6 The Drugs Price Control Order (DPCO), 1995
    • 3.3.7 Indian Patent Act 1970
    • 3.3.8 The Drugs Price Control Order (DPCO), 2013
    • 3.3.9 Good Clinical Practices (GCP)
    • 3.3.10 Good Laboratory Practices (GLP)
  • 3.4 Market Access
    • 3.4.1 Healthcare System
    • 3.4.2 Status of Health Technology Assessment (HTA)
    • 3.4.3 Pricing
    • 3.4.4 Reimbursement of Drugs

4. Indian Pharmaceutical Market: Discussions and Predictions 2019-2029

  • 4.1 Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume
  • 4.2 Indian Pharmaceuticals Market: Overall Revenue Forecast 2018-2029

5. Medical Treatment Needs in India, 2019-2029

  • 5.1 Disease Prevalence in India, 2019-2029
  • 5.2 Disease Incidence in India, 2019-2029
  • 5.3 Disease Mortality Rates in India, 2019-2029
    • 5.3.1 Top Causes of Death in India
    • 5.3.2 Top Causes of Death in India: Mortality Projections, 2019-2029

6. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2019-2029

  • 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2018
  • 6.2 Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2019-2029
  • 6.3 Infectious Disease Drugs: Overview, 2018
    • 6.3.1 Infectious Disease Drugs Market: Forecast, 2019-2029
    • 6.3.2 Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2018
    • 6.3.3 Lower Respiratory Tract Infections Among Leading Causes of Death
    • 6.3.4 Tuberculosis Still Rife in India
    • 6.3.5 Malaria, Risk and Opportunity
    • 6.3.6 HIV in India: Growing Therapeutic Area Worth Watching
    • 6.3.7 Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment
  • 6.4 Cardiovascular Therapeutics Segment: Overview, 2018
    • 6.4.1 Cardiovascular Disease - India's Leading Cause of Death, 2018
    • 6.4.2 Cardiovascular Drugs Market: Forecast, 2019-2029
  • 6.5 Gastro-Intestinal Therapeutic Segment: Overview, 2018
    • 6.5.1 Gastro-Intestinal Drugs Market: Forecast, 2019-2029
    • 6.5.2 Gastro-Intestinal Therapeutics in India: Challenges and Opportunities
    • 6.5.3 Drivers and Restraints for the Gastro-Intestinal Therapeutics Segment
  • 6.6 Respiratory Therapeutic Segment: Overview, 2018
    • 6.6.1 Respiratory Disease Drugs Market: Forecast, 2019-2029
    • 6.6.2 Drivers and Restraints for the Respiratory Therapeutics Segment
  • 6.7 Pain Relief / Analgesics Therapeutic Segment: Overview, 2018
    • 6.7.1 Pain Relief / Analgesics Drugs Market: Forecast, 2019-2029
    • 6.7.2 Drivers and Restraints for the Pain Relief/Analgesics Therapeutics Segment
  • 6.8 Diabetes Therapeutic Segment: Overview, 2018
    • 6.8.1 Diabetes Therapeutics Market: Forecast, 2019-2029
    • 6.8.2 Drivers and Restraints for the Diabetes Therapeutics Segment
  • 6.9 Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2018
    • 6.9.1 Vitamins / Minerals / Nutrients Therapeutics Market: Forecast, 2019-2029
    • 6.9.2 Vitamins / Minerals / Nutrients in India: Challenges and Opportunities
    • 6.9.3 Drivers and Restraints for the Vitamins / Minerals / Nutrients Therapeutics Segment
  • 6.10 Dermatological Therapeutic Segment: Overview, 2018
    • 6.10.1 Dermatological Therapeutics Market: Forecast, 2019-2029
    • 6.10.2 Drivers and Restraints for the Dermatological Therapeutics Segment
  • 6.11 Central Nervous System (CNS) Therapeutics: Overview, 2018
    • 6.11.1 CNS Drugs Market: Forecast, 2019-2029
    • 6.11.2 Intentional Injury Among the Top 10 Leading Causes of Death, 2018
    • 6.11.3 India's Aging Population: Driver for the CNS Segment
    • 6.11.4 Drivers and Restraints for the CNS Therapeutics Segment
  • 6.12 Gynaecological Treatment Market Overview: 2018
    • 6.12.1 Infant Mortality Still High in India
    • 6.12.2 Indian Gynaecological Treatments Market: Forecast, 2019-2029
    • 6.12.3 Drivers and Restraints for the Gynaecological Segment
  • 6.13 Other Pharmaceutical Products Market Overview: 2018
    • 6.13.1 Incidence of Cancer is Rising in India
    • 6.13.2 Indian Other Treatments Market: Forecast, 2019-2029

7. Indian Pharmaceutical Market: Leading Drug Types, 2019-2029

  • 7.1 Drug Types in the Indian Market: Overview, 2018
  • 7.2 Growth Forecasts for Leading Drug Types in India, 2019-2029
  • 7.3 Generic Drugs Dominate the Indian Pharmaceutical Market
    • 7.3.1 Indian Generics: Overview, 2018
    • 7.3.2 Indian Generic Drugs Market: Forecast, 2018-2029
    • 7.3.3 Branded Generics Preferred by Many Indian Patients
    • 7.3.4 Drivers and Restraints for the Generic Drug Market in India
  • 7.4 Indian Over-The-Counter (OTC) Drugs Market: Overview, 2018
    • 7.4.1 Indian OTC Market: Forecast, 2019-2029
    • 7.4.2 Drivers and Restraints of the Indian OTC Market
  • 7.5 Indian Patented Drugs Market: Overview, 2018
    • 7.5.1 Indian Patented Drugs Market: Forecasts, 2019-2029
    • 7.5.2 Drivers and Restraints for the Indian Patented Drugs Market
  • 7.6 Indian Biosimilar Drugs, 2018
    • 7.6.1 Indian Biosimilar Drugs Market: Forecast, 2019-2029
    • 7.6.2 A Number of Blockbuster Drugs Coming Off-Patent Over the Next Decade
    • 7.6.3 Drivers and Restraints of the Indian Biosimilar Drugs Market

8. The Leading Companies in the Indian Pharmaceuticals Market

  • 8.1 Indian Pharmaceuticals Market Overview
    • 8.1.1 Indian Pharmaceutical Patent Law and the Effect on Big Pharmaceutical Companies
  • 8.2 Top 50 Domestic Indian Pharmaceutical Companies, 2018
  • 8.3 Sun Pharmaceuticals Industries Limited
    • 8.3.1 Sun Pharma: Global Presence
      • 8.3.1.1 Sun Pharmaceutical Sales by Region, 2017
    • 8.3.2 Sun Pharmaceuticals Business Performance 2008-2017
    • 8.3.3 Sun Pharmaceutical: The Acquisition of Ranbaxy Laboratories is the Largest Ever Deal Made by an Indian Pharmaceutical Company
      • 8.3.3.1 Other Major M&A Activity
  • 8.4 Abbott Healthcare Private Limited (Abbott India)
    • 8.4.1 Abbott India: Business Performance 2007-2017
    • 8.4.2 Abbott India: Major and Recent M&A Activity
  • 8.5 Cipla Ltd.
    • 8.5.1 Cipla: Business Performance 2008-2017
    • 8.5.2 Cipla Ltd.: Major and Recent Activity
  • 8.6 Cadila Healthcare Limited
    • 8.6.1 Cadila: Business Performance 2008-2017
    • 8.6.2 Cadila Healthcare Revenue by Therapeutic Area 2017
  • 8.7 GlaxoSmithKline Pharmaceuticals Limited
    • 8.7.1 GlaxoSmithKline India: Business Performance 2008-2017
  • 8.8 Pfizer Limited., India
    • 8.8.1 Pfizer India: Business Performance 2008-2017
  • 8.9 Lupin
    • 8.9.1 Lupin: Business Performance 2008-2017
    • 8.9.2 Lupin Revenue by Therapeutic Area, 2017
  • 8.10 Sanofi India Limited
    • 8.10.1 Sanofi India Limited: Business Performance 2008-2017
    • 8.10.2 Sanofi India Limited Revenue by Business Segments, 2017
    • 8.10.3 Sanofi India Limited Revenue by Geographical Area, 2017
    • 8.10.4 Sanofi India Limited Recent Activities
  • 8.11 Intas Pharmaceuticals Limited
    • 8.11.1 Intas Pharmaceuticals Limited: Business Performance 2008-2017
  • 8.12 Dr. Reddy's Laboratories Ltd.
    • 8.12.1 Dr. Reddy's Laboratories Ltd: Business Performance 2008-2017
    • 8.12.2 Dr. Reddy's Laboratories Ltd. Revenue by Business Segments, 2017
    • 8.12.3 Dr. Reddy's Laboratories Ltd Global Generics Segment Revenue by Geographical Area, 2017
  • 8.13 Glenmark Pharmaceuticals Limited
    • 8.13.1 Glenmark Pharmaceuticals Limited: Business Performance 2008-2017
    • 8.13.2 Glenmark Pharmaceuticals Limited Revenue by Geographical Area, 2017
    • 8.13.3 Glenmark Pharmaceuticals Limited Recent Activities

9. Qualitative Analysis of the Indian Pharmaceuticals Market, 2018

  • 9.1 Indian Pharmaceutical Market: Drivers and Restraints
  • 9.2 SWOT Analysis of the Indian Pharmaceuticals Market
  • 9.3 Strengths
    • 9.3.1 Increasing Investment in the Healthcare System
    • 9.3.2 The Disease Burden and GDP Growing
    • 9.3.3 India's Population Set to Become the World's Largest by 2030
    • 9.3.4 India Popular for Pharmaceutical Outsourcing
  • 9.4 Weaknesses
    • 9.4.1 Stringent Pricing Regulations Hit the Indian Pharmaceuticals Market
    • 9.4.2 Poor Infrastructure Threatens to Hinder Market Potential
    • 9.4.3 Intense Competition Driving Down Drug Prices
  • 9.5 Opportunities
    • 9.5.1 Global Demand for Generics Rising
    • 9.5.2 National Rural Health Mission Driving Healthcare Access in Rural Areas
    • 9.5.3 Significant Investment from MNCs Expected
    • 9.5.4 Innovative Biotechnology Sector Set to Capitalise on Patent Expiries
  • 9.6 Threats
    • 9.6.1 Rise of Other Low-Cost Generic Exporters
    • 9.6.2 Will the Indian Government Stick to Increasing Healthcare Expenditure?
    • 9.6.3 Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals
  • 9.7 Porter's Five Forces Analysis of the Indian Pharmaceuticals Market
    • 9.7.1 Rivalry Among Competitors [High]
    • 9.7.2 Threat of New Entrants [Low]
    • 9.7.3 Power of Suppliers [Medium]
    • 9.7.4 Power of Buyers [High]
    • 9.7.5 Threat of Substitutes [Low]

10. Conclusion

  • 10.1 The Indian Pharmaceuticals Market: Growing Global Market Share
  • 10.2 Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent
  • 10.3 Commercial Drivers of the Indian Pharmaceuticals Market
  • 10.4 Commercial Restraints of the Indian Pharmaceuticals Market
  • 10.5 Concluding Remarks

11. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 4.1 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Table 5.2 Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014
  • Table 5.3 Causes of Death in India by World Ranking, 2014
  • Table 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2018, 2024, 2029
  • Table 6.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2018-2029
  • Table 6.3 The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.4 The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.5 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.6 The Indian Respiratory Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.7 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.8 Indian Diabetes Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.9 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.10 Indian Dermatological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.11 Indian CNS Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.12 Indian Gynaecological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.13 Indian Other Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2019, 2024 and 2029
  • Table 7.2 Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2019-2029
  • Table 7.3 Indian Generic Drugs Market: Revenue ($bn), AGR (%) and CAGR (%) 2018-2029
  • Table 7.4 Indian OTC Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.5 Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.6 Selected Biosimilar Therapeutics on the Indian Market, 2018
  • Table 7.7 Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.8 Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028
  • Table 7.9 Selected Late-Stage Biosimilar Pipeline Products, 2015
  • Table 8.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs. m), Revenue ($m) and Market Share (%), 2017
  • Table 8.2 Sun Pharmaceuticals: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Business Area, FY 2017
  • Table 8.3 Sun Pharmaceuticals: Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.4 Sun Pharmaceuticals: M&A Activity, 1997-2016
  • Table 8.5 Abbott India: Market Share (%) and Market Rank of Key Brands
  • Table 8.6 Abbott India: Revenue (Rs. m), AGR (%) and CAGR (%), 2006-2017
  • Table 8.7 Cipla: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.8 Cipla: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2017
  • Table 8.9 Cadila Healthcare Ltd.: Total Revenue (Rs. m), Total Revenue ($m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.10 Cadila Healthcare Ltd.: Revenue (Rs.m) and Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.11 GlaxoSmithKline India: Key Products in the Indian Market, 2017
  • Table 8.12 GlaxoSmithKline India Total Revenue (Rs. m), AGR (%) and CAGR (%), 2007-2017
  • Table 8.13 Pfizer India: Leading Brands on the Indian Market 2017
  • Table 8.14 Pfizer India: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.15 Lupin: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.16 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.17 Sanofi India Limited: Major Products,2017
  • Table 8.18 Sanofi India Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.19 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Domestic Segment, 2017
  • Table 8.20 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Branded drugs, 2017
  • Table 8.21 Sanofi India Limited: Revenue (Rs. m), and Revenue Share (%) by Geographical Area, 2017
  • Table 8.22 Intas Pharmaceuticals Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.23 Dr. Reddy's Laboratories Ltd: Major Products,2017
  • Table 8.24 Dr. Reddy's Laboratories Ltd: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.25 Dr. Reddy's Laboratories Ltd: Revenue (Rs. m), and Revenue Share (%) by Business Segment, 2017
  • Table 8.26 Dr. Reddy's Laboratories Ltd: Revenue (Rs.m), and Revenue Share (%) by Geographical Area, 2017
  • Table 8.27 Glenmark Pharmaceuticals Limited: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 9.1 SWOT Analysis of the Indian Pharmaceuticals Market

List of Figures

  • Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets
  • Figure 2.1 Indian Population: Rural and Urban (Mn),1960-2020
  • Figure 2.2 Indian Population: Total (Mn) and Annual Population Growth Rate (%), 1960-2020
  • Figure 2.3 Indian GDP ($bn) and Growth Rate (%), 2010-2020
  • Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2008-2020
  • Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2014
  • Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2008-2014
  • Figure 3.1 National Regulatory Bodies Regulating the Indian Pharmaceutical Market
  • Figure 4.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Figure 6.1 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2018
  • Figure 6.2 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2024
  • Figure 6.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 6.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
  • Figure 6.6 Infectious Diseases Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.8 Cardiovascular Diseases Therapeutics Market in India: Drivers and Restraints
  • Figure 6.9 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.10 Gastro-intestinal Therapeutics Market in India: Drivers and Restraints
  • Figure 6.11 Indian Respiratory Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.12 Respiratory Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.13 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.14 Pain Relief/Analgesics Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.15 Indian Diabetes Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.16 Diabetes Therapeutics Market in India: Drivers and Restraints
  • Figure 6.17 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.18 Vitamins / Minerals / Nutrients Therapeutics Market in India: Drivers and Restraints
  • Figure 6.19 Indian Dermatological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.20 Dermatological Therapeutics Market in India: Drivers and Restraints
  • Figure 6.21 Indian CNS Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.22 CNS Therapeutics Market in India: Drivers and Restraints
  • Figure 6.23 Indian Gynaecological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.24 Gynaecological Therapeutics Market in India: Drivers and Restraints
  • Figure 6.25 Indian Other Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2019
  • Figure 7.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2024
  • Figure 7.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 7.4 Indian Generic Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.5 Generic Drugs Market in India: Drivers and Restraints
  • Figure 7.6 Indian OTC Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.7 OTC Drugs Market in India: Drivers and Restraints
  • Figure 7.8 Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.9 Patented Drugs Market in India: Drivers and Restraints
  • Figure 7.10 Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.11 Biosimilar Drug Market in India: Drivers and Restraints
  • Figure 8.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, FY 2017
  • Figure 8.2 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.3 Abbott India: Revenue (Rs. m) and AGR (%), 2006-2017
  • Figure 8.4 Cipla Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 8.5 Cadila Healthcare Ltd.: Revenue Share (%), by Business Area, 2017
  • Figure 8.6 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2007-2017
  • Figure 8.7 Pfizer India: Revenue (Rs.m) and AGR (%), 2007-2016
  • Figure 8.8 Lupin: Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 8.9 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Figure 8.10 Sanofi India Limited: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.11 Sanofi India Limited: Revenue Distribution by Business Segments, 2017
  • Figure 8.12 Sanofi India Limited: Revenue Distribution by Domestic Segments, 2017
  • Figure 8.13 Sanofi India Limited: Revenue Distribution by Geographical Area, 2017
  • Figure 8.14 Intas Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.15 Dr. Reddy's Laboratories Ltd: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.16 Dr. Reddy's Laboratories Ltd: Revenue Distribution by Business Segments, 2017
  • Figure 8.17 Dr. Reddy's Laboratories Ltd: Global Generics Segment Revenue Distribution by Geographical Area, 2017
  • Figure 8.18 Glenmark Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2007-2017
  • Figure 8.19 Glenmark Pharmaceuticals Limited: Revenue Distribution by Geographical Area, 2017
  • Figure 9.1 Indian Pharmaceuticals Market: Drivers and Restraints
  • Figure 9.2 Porter's Five Forces Analysis of the Indian Pharmaceuticals Market

COMPANIES LISTED:

  • Abbott India
  • Able Labs
  • Ajanta Pharma Ltd
  • Akumentis Healthcare Ltd
  • Albert David Ltd
  • Alembic
  • Alkem
  • Almirall
  • Amgen
  • Apex Laboratories Pvt. Ltd
  • Aristo Pharma
  • Ascendis Pharma
  • AstraZeneca
  • Aventis Pharma Limited
  • Bayer
  • Bharat Serums
  • Biocon Ltd
  • Biosintez
  • Blue Cross Laboratories Ltd.
  • Cadila Healthcare Ltd.
  • Caraco
  • Chattem Chemicals, Inc.
  • Cipla
  • Claris Lifesciences
  • Daiichi Sankyo
  • Divis Laboratories
  • Dr. Reddy's Laboratories
  • DUSA Pharma, Inc.
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Emcare
  • Eris Lifesciences
  • Exelan
  • FDC
  • Fourrts (India) Laboratories Pvt, Ltd
  • Franco India
  • GlaxoSmithKline India
  • Glenmark Pharma
  • GSK India
  • Heinz India
  • Helsinn Group
  • Hetero Drugs Ltd
  • Hoechst India Limited
  • Hoechst Marion Roussel Limited
  • Hoechst Pharmaceuticals Private Limited
  • Indoco
  • Indi Pharma Pvt. Ltd.
  • InSite Vision
  • Intas Pharma
  • InvaGen
  • Ipca Laboratories
  • Janssen
  • JB Chemicals
  • JSC Biosintez
  • Lonza
  • Lupin
  • Macleods
  • MannKind Corporation
  • Medley Pharmaceuticals Ltd
  • MedproPhamaceutica (Pty) Ltd
  • Megafine Pharma
  • Merck KGaA
  • Meyer Organics
  • Micro Labs
  • MSD Pharma
  • Natco
  • Novartis India
  • Novo Nordisk
  • Odomzo
  • Pfizer India
  • Pharmalucence
  • Piramal Healthcare
  • Pola Pharma, Inc.
  • Ranbaxy
  • Raptakos, Brett & Co. Ltd
  • Roche Pharma India
  • Sandoz, Novartis Division
  • Sanofi India
  • Seciera
  • Sun Pharmaceuticals
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals (Pty)Ltd
  • The Himalaya Drug Company
  • Torrent Pharma
  • True North
  • Unichem
  • URL's
  • USV
  • Wallace Pharmaceuticals
  • Win-Medicare
  • Wockhardt
  • Wockhardt
  • Zydus Wellness Ltd

List of Organizations Mentioned in the Report:

  • Australia's TGA (Therapeutic Goods Administration)
  • Central Drugs Standard Control Organisation
  • Competition Commission of India (CCI)
  • Dr. M.G.R. Medical University (TNMGRMU)
  • Drug Consultative Committee
  • Drug Controller General of India
  • Medical Council of India
  • MHLW (Ministry of Health, Labour and Welfare)
  • MHRA (Medicines & Healthcare Products Regulatory Agency)
  • Ministry of Chemicals & Fertilisers
  • Ministry of Health and Family Welfare
  • National AIDS Control Organisation (NACO)
  • National Pharmaceutical Pricing Authority
  • Organisation for Economic Co-operation and Development (OECD)
  • State Food and Drug Administrations
  • The Joint United Nations Programme on HIV/AIDS (UNAIDS)
  • US Federal Trade Commission (FTC)
  • World Health Organization (WHO)